temozolomide has been researched along with ginsenosides in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, F; Ling, Z; Sun, C; Wang, L; Wang, S; Wu, B; Xia, L; Yu, Y | 1 |
| Chen, Z; Shen, L; Wei, X; Zheng, X; Zhu, H | 1 |
2 other study(ies) available for temozolomide and ginsenosides
| Article | Year |
|---|---|
Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Gene Expression Regulation, Neoplastic; Ginsenosides; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Rats; Temozolomide; Xenograft Model Antitumor Assays | 2016 |
20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Ginsenosides; Glioblastoma; Humans; Male; Mice, Nude; O(6)-Methylguanine-DNA Methyltransferase; Temozolomide; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2019 |